SLC9A1 and chronic myelogenous leukemia, BCR-ABL1 positive: To conclude, inhibition of HO-1 reduces CML IM resistance, and the above-discussed studies confirm this and simultaneous inhibition of HO-1 combined with NHE1, HDACs, as well as simultaneous inhibition of HO-1 and BCR-ABL by hybrid compounds (HO-1+IM), have promising results and could be helpful in the removal of IM-resistant cells.